rs2229765 — IGF1R c.3179G>A (E1013E)

Synonymous IGF1R variant associated with lower circulating IGF-1 levels and enrichment in long-lived populations — affects mRNA splicing despite preserving the amino acid sequence

See your personal result for IGF1R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

IGF1R c.3179G>A — The Receptor Variant That May Help You Live Longer

Of all the genetic pathways linked to longevity, the insulin/IGF-1 signaling (IIS) pathway11 insulin/IGF-1 signaling (IIS) pathway
The IIS pathway coordinates growth, metabolism, and stress response across almost all animals. When signaling is reduced, cells shift from growth mode into maintenance and repair mode, which appears to extend lifespan in every organism tested from yeast to primates is the most replicated. This variant in IGF1R — the gene encoding the insulin-like growth factor 1 receptor — sits at the very hub of that pathway. It is a synonymous variant, meaning the DNA change does not alter the protein sequence. Yet despite this "silent" appearance, carriers of the A allele consistently show lower circulating IGF-1 levels and are overrepresented among people who live the longest.

The Mechanism

The variant is a G-to-A change at position 3179 of the IGF1R coding sequence, within exon 16. Both the G and A versions of codon 1013 encode the same amino acid (glutamic acid), which is why this is classified as synonymous. So why does it matter?

Synonymous mutations can powerfully affect gene function22 Synonymous mutations can powerfully affect gene function
So-called "silent" mutations can alter mRNA secondary structure, disrupt exonic splicing enhancers or silencers, change codon usage (affecting translation speed and protein folding), and alter mRNA stability — none of which are detectable at the amino acid level through several mechanisms not visible at the protein level. For rs2229765, the predominant hypothesis is that the G-to-A change disrupts an exonic splicing enhancer33 exonic splicing enhancer
ESEs are short sequences within exons recognized by SR proteins. They promote inclusion of the surrounding exon in the final mRNA. Disrupting an ESE can cause exon skipping, leading to a shorter, sometimes less functional receptor protein, shifting the balance of IGF1R mRNA splice isoforms. The result appears to be subtly reduced functional receptor at the cell surface, which in turn leads to lower circulating free IGF-1 (since IGF-1 in the bloodstream is partly regulated by its receptor's clearance and feedback activity).

The Evidence

The foundational human study came from Bonafe et al. in 200344 Bonafe et al. in 2003
Bonafe M et al. Polymorphic variants of insulin-like growth factor I (IGF-I) receptor and phosphoinositide 3-kinase genes affect IGF-I plasma levels and human longevity. J Clin Endocrinol Metab, 2003. In an Italian population study comparing 278 young-to-middle-aged adults (17-85 years) with 218 very long-lived individuals (86-109 years), carriers of the A allele had lower free plasma IGF-1 levels and were significantly more common among the oldest group.

The TRELONG (Treviso Longeva) study confirmed and extended this in a larger, longitudinal Italian cohort of 668 subjects aged 70-106. Albani et al. 200955 Albani et al. 2009
Albani D et al. A polymorphic variant of the insulin-like growth factor 1 (IGF-1) receptor correlates with male longevity in the Italian population. BMC Geriatrics, 2009 found a sex-specific pattern: in men, the A allele frequency increased from 34.4% in the 70-85 age group to 43.7% among those 85 and older (p=0.04). Men with the AA genotype had the lowest IGF-1 levels in the oldest cohort (mean 119 ± 50 ng/mL, versus 185 ± 74 ng/mL in GG men). A subsequent prospective follow-up of this cohort Albani et al. 201166 Albani et al. 2011
Albani D et al. Insulin-like growth factor 1 receptor polymorphism rs2229765 and circulating interleukin-6 level affect male longevity in a population-based prospective study. Aging Male, 2011 found that AA males had a 76% reduced mortality risk compared to GG males (OR 0.24, 95% CI 0.07-0.64, p=0.008). The effect was not replicated in women, suggesting sex-specific biology in IIS pathway regulation of aging.

A gene combination study Barbieri et al. 201277 Barbieri et al. 2012
Barbieri M et al. A/Asp/Val allele combination of IGF1R, IRS2, and UCP2 genes is associated with better metabolic profile, preserved energy expenditure parameters, and low mortality rate in longevity. Age (Dordr), 2012 found that the A allele of IGF1R combined with specific variants in IRS2 (Asp allele) and UCP2 (Val allele) was associated with a 3.2-fold increased probability of reaching extreme old age (OR 3.185, 95% CI 1.63-6.19, p=0.0006) in 722 Italian subjects. This combination was also associated with lower insulin resistance, preserved resting metabolic rate, and better energy expenditure parameters.

A meta-analysis of four studies88 meta-analysis of four studies
Di Bona D et al. Association between genetic variations in the insulin/insulin-like growth factor (IGF-1) signaling pathway and longevity: a systematic review and meta-analysis. Curr Vasc Pharmacol, 2014 found that across available data, subjects carrying the A allele of rs2229765 had a significantly greater probability of longevity. Evidence level is moderate: findings are replicated across multiple Italian cohorts, but populations studied are geographically limited and sex-specific effects complicate interpretation.

Practical Implications

This variant acts through reduced IIS signaling. The same pathway is modified by protein intake (protein directly raises IGF-1 levels), periodic fasting, and dietary patterns. Carriers of the A allele who wish to leverage the IGF-1-lowering benefit that appears genetically advantageous can amplify it through targeted dietary choices — primarily moderating protein intake during midlife. The key evidence base here comes from studies showing protein restriction substantially reduces IGF-1 in humans, with most longevity benefit concentrated in the 50-65 age range for moderate protein reduction.

Monitoring serum IGF-1 allows calibration of diet and lifestyle interventions. Total IGF-1 of 100-175 ng/mL in adults is generally associated with the longevity range, while levels above 200 ng/mL have been linked to increased cancer risk in multiple epidemiological studies.

Interactions

The strongest documented interaction is with IRS2 (rs1805097, the Asp/Gly variant) and UCP2 (rs659366, the Val/Ala variant). When all three genes carry their "longevity" alleles (IGF1R-A, IRS2-Asp, UCP2-Val), the longevity association is dramatically amplified (OR 3.185 vs ~1.3 for any single variant alone). This reflects the IIS pathway's interconnected nature: IGF1R sits upstream, IRS2 is the intracellular docking protein it signals through, and UCP2 modulates the mitochondrial energy dissipation that determines how cells respond to reduced IIS signaling. Variants in PI3K pathway genes that work downstream of IGF1R may further modify this effect.

IGF-1 levels are also influenced by variants in the IGF1 gene itself (particularly rs35767 in the promoter region, which affects IGF-1 transcription). Carrying the IGF1R A allele alongside IGF1 promoter variants that reduce IGF-1 production could compound the IIS reduction further.

Genotype Interpretations

What each possible genotype means for this variant.

GG Standard-IIS Profile Normal

Common GG genotype — typical IGF-1 signaling, no longevity-associated benefit from this variant

The absence of the A allele means you do not carry the IGF-1 lowering effect documented for this variant. This is not a disease-causing variant — GG is the common genotype and the majority of people who live long, healthy lives carry it. The longevity association of the A allele is a population-level statistical enrichment, not a deterministic effect.

For GG individuals, the IIS pathway can still be modulated through lifestyle: dietary protein calibration and periodic fasting both meaningfully influence circulating IGF-1 levels. The interventions that would be genetically "free" for A allele carriers require intentional behavioral commitment for GG carriers.

AA Low-IIS Profile Beneficial

Both copies of the longevity-associated A allele — lowest IGF-1 levels in aging males

The AA genotype produces the most reduced functional IGF1R signaling of the three possible genotypes. In the TRELONG cohort, AA men 85 years and older had mean IGF-1 levels of 119 ± 50 ng/mL, compared to 185 ± 74 ng/mL in GG men of the same age — a 36% difference. This aligns with the centenarian biology: in Ashkenazi Jewish centenarians studied by Barzilai and colleagues, IGF1R mutations that reduced receptor activity were overrepresented, and these centenarians had paradoxically elevated total IGF-1 (the body compensating for reduced receptor sensitivity by producing more ligand).

The practical implication is that your genetically lower IIS signaling is likely helping rather than hurting you. The goal is not to suppress IGF-1 further below a healthy floor — very low IGF-1 (<80 ng/mL) is associated with frailty and muscle loss in older adults. Rather, it is to keep IGF-1 in the range associated with longevity (typically 100-175 ng/mL in midlife adults) through dietary calibration, and to monitor that it does not climb into the range (>200 ng/mL) linked to cancer risk.

The gene combination study (Testa et al.) found that the longevity benefit of the A allele is substantially amplified when IRS2 and UCP2 co-carry their longevity variants — worth checking if you use a platform reporting those SNPs.

AG Intermediate-IIS Profile Intermediate

One longevity-associated A allele — moderately lower IGF-1 signaling

The meta-analysis of four studies (Di Bona et al. 2014) found that the longevity association of IGF1R rs2229765 is observed across A-bearing genotypes (AG and AA combined vs GG), though the most pronounced effects in prospective survival data are in the AA group. You carry one beneficial allele, which places your IIS signaling in an intermediate zone.

In practice, this means your IGF-1 levels under typical dietary conditions will tend to be somewhat lower than the GG average, which is a mild advantage from a longevity standpoint. Monitoring is valuable to understand where your personal set point falls and whether dietary adjustments would help.